Yukihiro Namba
Overview
Explore the profile of Yukihiro Namba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maeda N, Ikeda K, Matsumoto M, Namba Y
J Liposome Res
. 2016 Aug;
27(3):221-227.
PMID: 27572825
Phospholipids and cholesterols are being spotlighted as raw materials for preparing liposomes, one of the key compounds for drug delivery systems (DDS), and as base compounds for converting water-soluble drugs...
2.
Maeda N, Miyazawa S, Shimizu K, Asai T, Yonezawa S, Kitazawa S, et al.
Biol Pharm Bull
. 2006 Sep;
29(9):1936-40.
PMID: 16946513
We previously observed the enhanced anticancer efficacy of anticancer drugs encapsulated in Ala-Pro-Arg-Pro-Gly-polyethyleneglycol-modified liposome (APRPG-PEG-Lip) in tumor-bearing mice, since APRPG peptide was used as an active targeting tool to angiogenic...
3.
Ichikawa K, Hikita T, Maeda N, Yonezawa S, Takeuchi Y, Asai T, et al.
Biochim Biophys Acta
. 2005 Apr;
1669(1):69-74.
PMID: 15843001
For the improvement of therapeutic efficacy in photodynamic therapy (PDT) by using a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD-MA), we previously prepared polyethylene glycol (PEG)-modified liposomes encapsulating BPD-MA (PEG-Lip...
4.
Oku N, Namba Y
Methods Enzymol
. 2005 Feb;
391:145-62.
PMID: 15721379
Liposomes are useful as drug carriers in drug delivery systems, especially for drugs with severe side effects such as antitumor agents. The conventional formulations of liposomes are opsonized by plasma...
5.
Maeda N, Takeuchi Y, Takada M, Sadzuka Y, Namba Y, Oku N
J Control Release
. 2004 Oct;
100(1):41-52.
PMID: 15491809
For the purpose of cancer anti-neovascular therapy (ANET), we previously isolated 5-mer peptide Ala-Pro-Arg-Pro-Gly (APRPG) that specifically bound to the tumor angiogenic site and observed that APRPG-modified liposomes encapsulating adriamycin...
6.
Takeuchi Y, Ichikawa K, Yonezawa S, Kurohane K, Koishi T, Nango M, et al.
J Control Release
. 2004 Jun;
97(2):231-40.
PMID: 15196750
Previous study indicated that antiangiogenic photodynamic therapy (PDT), laser irradiation at 15 min post-injection of photosensitizer in vivo, is effective for cancer treatment, and a photosensitizer, benzoporphyrin derivative monoacid ring...
7.
Ichikawa K, Takeuchi Y, Yonezawa S, Hikita T, Kurohane K, Namba Y, et al.
Cancer Lett
. 2004 Mar;
205(1):39-48.
PMID: 15036659
We previously observed that antiangiogenic photodynamic therapy (PDT), namely, laser irradiation at 15 min after administration of photosensitizer, by using stable liposomal benzoporphyrin derivative monoacid ring A (BPD-MA), in which...
8.
Maeda N, Takeuchi Y, Takada M, Namba Y, Oku N
Bioorg Med Chem Lett
. 2004 Mar;
14(4):1015-7.
PMID: 15013013
For the purpose of cancer antineovascular therapy, a novel angiogenesis-targeted peptide, Ala-Pro-Arg-Pro-Gly, (APRPG) was attached to hydrophobized polyethylene glycol (distearoylphosphatidylethanolamine [DSPE]-PEG). DSPE-PEG and the 5-mer peptide were condensed with DCC-HOBt...
9.
PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy
Ichikawa K, Hikita T, Maeda N, Takeuchi Y, Namba Y, Oku N
Biol Pharm Bull
. 2004 Mar;
27(3):443-4.
PMID: 14993821
For the purpose of the avoidance of reticuloendothelial system (RES)-trapping, liposome entrapped benzoporphyrin derivative monoacid ring A (BPD-MA), which is used for cancer photodynamic therapy (PDT), was modified with polyethylene...
10.
Oku N, Asai T, Kurohane K, Watanabe K, Kuromi K, Namba Y, et al.
Cell Mol Biol Lett
. 2002 Jul;
7(2):247-8.
PMID: 12097936
No abstract available.